Galectin-9 (Gal-9) is a glycan-binding protein (lectin) representing an attractive new cancer immunotherapeutic target owing to its pleiotropic roles in immune and tumor cell-intrinsic functions, including in activation, proliferation, and trafficking [3]. The gene discussed is LGALS9; the disease is neoplasm.